News
OBIO
4.640
-1.49%
-0.070
Weekly Report: what happened at OBIO last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at OBIO last week (0401-0405)?
Weekly Report · 04/08 12:03
Weekly Report: what happened at OBIO last week (0325-0329)?
Weekly Report · 04/01 12:00
Orchestra BioMed Holdings Inc: Statement of changes in beneficial ownership of securities
Press release · 03/29 02:34
Orchestra BioMed Hldgs Price Target Maintained With a $20.00/Share by Chardan Capital
Dow Jones · 03/28 12:59
Orchestra BioMed Hldgs Is Maintained at Buy by Chardan Capital
Dow Jones · 03/28 12:59
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
Benzinga · 03/28 12:49
Piper Sandler Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)
TipRanks · 03/28 10:55
Orchestra BioMed Hldgs Q4 EPS $(0.37) Beats $(0.38) Estimate, Sales $262.00K Miss $990.00K Estimate
Orchestra BioMed Hldgs reported quarterly losses of $0.37 per share. The company reported quarterly sales of $262.00 thousand which missed the analyst consensus estimate by 73.54%. The company beat the analyst estimate by 2.63 percent in the quarter.
Benzinga · 03/28 03:46
OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q4 2023
Orchestra BioMed Hldgs reported earnings per share of -37 cents. The company reported revenue of $262,000. This was 73.54% worse than the analyst estimate for the company to report revenue of   The company also reported lower than expected earnings.
Investorplace · 03/28 02:53
Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Clinical Data
TipRanks · 03/27 23:35
Orchestra BioMed reports FY results
Orchestra BioMed Holdings, Inc. Reports FY results. Net loss for 2023 was $49.1 million, or $1.48 per share. Cash and cash equivalents and marketable securities totaled $87.6 million as of December 31, 2023.
Seeking Alpha · 03/27 20:52
*Orchestra BioMed Holdings 2023 Loss/Shr $1.48 >OBIO
Dow Jones · 03/27 20:19
*Orchestra BioMed Holdings 2023 Rev $2.8M >OBIO
Dow Jones · 03/27 20:19
Press Release: Orchestra BioMed Reports Full Year -3-
Net loss per share for the quarter ended March 27, 2024 is $1.48 per share. The company has a net loss of $33.6 million. The company expects to make a profit in the first quarter of 2024. The Company's stock price is expected to rise to $7.50 per share in the second quarter.
Dow Jones · 03/27 20:17
Press Release: Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors Orchestra BioMed is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Mr.Pacitti brings nearly 30 years of experience in cardiovascular device and procedural imaging. He is currently the President of Siemens Medical Solutions USA and Head of the Americas.
Dow Jones · 03/26 12:00
Weekly Report: what happened at OBIO last week (0318-0322)?
Weekly Report · 03/25 12:03
Weekly Report: what happened at OBIO last week (0311-0315)?
Weekly Report · 03/18 12:01
Orchestra BioMed Demonstrates Strength Of Cardiovascular Pipeline With Virtue SAB And AVIM Therapy Presentations At CRT 2024 Annual Meeting
Orchestra BioMed Holdings, Inc. Announced two oral presentations at the Cardiovascular Research Technologies 2024 Meeting in Washington, D.C. Virtue Sirolimus AngioInfusion Balloon is a novel drug-eluting balloon angioplasty system. New pharmacokinetic data demonstrate Virtue SAB enables extended release of sirolims without polymer degradation. A second presentation featured clinical data on AVIM therapy, an investigational therapy to lower blood pressure.
Benzinga · 03/13 12:10
Weekly Report: what happened at OBIO last week (0304-0308)?
Weekly Report · 03/11 11:56
More
Webull provides a variety of real-time OBIO stock news. You can receive the latest news about Orchestra BioMed Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company seeking to provide solutions for unmet needs in procedure-based medicine. The Company’s flagship product candidates are Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of artery disease, the leading cause of mortality worldwide, and BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension, a significant risk factor for death worldwide. Virtue SAB is a drug/device combination product candidate for the treatment of artery disease designed to deliver an extended-release formulation of sirolimus, SirolimusEFR, during balloon angioplasty without the need for balloon coating or a permanent implant. BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate, substantial and persistent reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction.